2-丙基吡咯烷 | 1121-44-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 2-丙基吡咯烷
• 英文名称: 2-Propyl-pyrrolidin
• 英文别名: 2-propylpyrrolidine
• CAS: 1121-44-4
• 化学式: C₇H₁₅N
• 分子量: 113.203
• InChiKey: ICALDHCMXFGLBN-UHFFFAOYSA-N

物化性质

• 熔点：
  193-194 °C
• 沸点：
  66-67 °C(Press: 30 Torr)
• 密度：
  0.8259 g/cm3
• 保留指数：
  916

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-丙基吡咯烷 、 N-[6-chloro-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-yl]acetamide 以 1,4-二氧六环 为溶剂， 反应 2.0h， 生成 N-[2-(3,5-dimethylpyrazol-1-yl)-6-(2-propylpyrrolidin-1-yl)pyrimidin-4-yl]acetamide
  参考文献：
  名称：

  N-[6-Amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A_2A Receptor Antagonists with Improved Drug Like Properties and in Vivo Efficacy

  摘要：

  In the present article, we report on a strategy to improve the physical properties of a series of small molecule human adenosine 2A (hA(2A)) antagonists. One of the aromatic rings typical of this series of antagonists is replaced with a series of aliphatic groups, with the aim of disrupting crystal packing of the molecule to lower the melting point and in turn to improve the solubility. Herein, we describe the SAR of a new series of water-soluble 2,4,6-trisubstituted pyrimidines where R-1 is an aromatic heterocycle, R-2 is a short-chain alkyl amide, and the typical R-3 aromatic heterocyclic substituent is replaced with an aliphatic amino substituent. This approach significantly enhanced aqueous solubility and lowered the log P of the system to provide molecules without significant hERG or CYP liabilities and robust in vivo efficacy.

  DOI：

  10.1021/jm800908d
• 作为产物：
  描述：

  (N-tert-Butyloxycarbonyl)heptylamine 在 碘苯二乙酸 、 三氟乙酸 、 sodium iodide 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成 2-丙基吡咯烷
  参考文献：
  名称：

  三碘化物介导的仲CH键的δ胺化

  摘要：

  与c δ -H的未活化的，仲C-H键以形成宽范围的官能化的吡咯烷的已经由三碘化物开发胺化（I 3 - ）-介导的策略。通过原位1）碘化钠和2）的螯合的氧化瞬时产生碘（I 2）为我3 - ，该方法排除了不希望的我2介导的分解，否则可以限制合成实用程序来仅弱C（SP 3） -H键。NMR和UV / Vis数据以及被拦截的中间体均支持这种由三碘化物介导的无偏，次级C（sp 3）-H键通过热或光解引发的环化机理。

  DOI：

  10.1002/anie.201604704

文献信息

• CHEMICAL COMPOUNDS
  申请人：Deng Jianghe

  公开号：US20090143372A1

  公开（公告）日：2009-06-04

  The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula I: where R1, R2, R3, U and V are defined below and to pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  这项发明涉及新型吲哚羧酰胺衍生物。具体而言，该发明涉及符合以下式I的化合物： 其中R1、R2、R3、U和V如下定义，并且其药学上可接受的盐。该发明的化合物是IKK2的抑制剂，可用于治疗与不当IKK2（也称为IKKβ）活性相关的疾病，如类风湿性关节炎、哮喘和慢性阻塞性肺病（COPD）。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制IKK2活性和治疗相关疾病的方法。
• [EN] BICYCLIC INHIBITORS OF PAD4<br/>[FR] INHIBITEURS BICYCLIQUES DE PAD4
  申请人：PADLOCK THERAPEUTICS INC

  公开号：WO2017100594A1

  公开（公告）日：2017-06-15

  The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

  本发明提供了用作PAD4抑制剂的化合物、其组合物以及治疗与PAD4相关疾病的方法。
• METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER
  申请人：Cyteir Therapeutics, Inc.

  公开号：US20200397760A1

  公开（公告）日：2020-12-24

  This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat pancreatic cancer.

  这个应用程序是针对由以下结构式代表的RAD51抑制剂，以及它们的使用方法，例如用于治疗胰腺癌。
• [EN] CANNABINOID RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS DES CANNABINOÏDES
  申请人：ARENA PHARM INC

  公开号：WO2012116279A1

  公开（公告）日：2012-08-30

  Provided are certain methods useful in the treatment of pain comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor.

  提供了一些在治疗疼痛方面有用的方法，包括给予化合物Ia的复方及其药物组合物，以调节大麻素CB2受体的活性。
• Benzene, Pyridine, and Pyridazine Derivatives
  申请人：Huang He Kenneth

  公开号：US20080076813A1

  公开（公告）日：2008-03-27

  Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein A, Q 1 , Q 2 , Q 3 , R 3 , and R 4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  本发明涉及公式I的化合物和药用可接受的盐，其中A、Q1、Q2、Q3、R3和R4如本文所定义。公式I的化合物在治疗与细胞增殖相关的疾病和/或病况方面具有用途，如癌症、炎症、关节炎、血管生成等。还公开了包括本发明化合物的药物组合物以及使用这些化合物治疗上述病况的方法。